Correspondence from UK oncologists seeks better understanding of the real-world applicability of LAURA, and the trialists clarify that over two-thirds of screening failures for enrollment were due to lack of EGFR-mutation confirmation (not poor performance status) and explain how PET staging (or lack thereof) was unlikely to bias the placebo arm to more baseline occult metastatic disease. | Banna & Addeo, N Engl J Med 2024
